<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104298</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS-20</org_study_id>
    <secondary_id>2008-008922-55</secondary_id>
    <nct_id>NCT01104298</nct_id>
  </id_info>
  <brief_title>Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS</brief_title>
  <official_title>Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed investigation intends to explore if the combination of trabectedin and&#xD;
      doxorubicin in the first line of treatment of advanced sarcomas obtains better results than&#xD;
      doxorubicin monotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed investigation intends to explore if the combination of trabectedin and&#xD;
      doxorubicin in the first line of treatment of advanced sarcomas obtains better results than&#xD;
      doxorubicin monotherapy.&#xD;
&#xD;
      This proposal arises from the need to bring to the first line of treatment of advanced STS&#xD;
      agents that have shown activity in second line. The goal is to improve available standard&#xD;
      treatments. Tumors in patients not previously exposed to chemotherapy have not been selected&#xD;
      in their biological behavior and they are the best scenario to test antitumor activity of a&#xD;
      new anticancer drug.&#xD;
&#xD;
      The combination of drugs with different mechanisms of action may be a clear advantage to&#xD;
      obtain better results and potential synergy. On the other hand, the toxicity profiles of both&#xD;
      study drugs are different and worsening or summative of adverse effects is not expected.&#xD;
&#xD;
      The purpose of this study is to determine the efficacy of the combination of trabectedin and&#xD;
      doxorubicin in comparison with doxorubicin alone in patients with advanced non operable&#xD;
      and/or metastatic Soft Tissue Sarcomas (STS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis did not show good results for main objective&#xD;
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS)</measure>
    <time_frame>2012</time_frame>
    <description>To determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS). To this end, progression free survival will be compared between both groups of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine activity by means of RECIST objective responses in both study arms, trabectedin/doxorubicin combination and the control arm.</measure>
    <time_frame>2012</time_frame>
    <description>To determine activity by means of RECIST objective responses in both study arms, trabectedin/doxorubicin combination and the control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the tumor control (response rates plus stabilizations) in both arms of treatment.</measure>
    <time_frame>2012</time_frame>
    <description>To determine the tumor control (response rates plus stabilizations) in both arms of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>2012</time_frame>
    <description>Overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine activity by tissue changes applying the Choi criteria to Soft Tissue Sarcomas (STS)(see radiological review sub study).</measure>
    <time_frame>2012</time_frame>
    <description>To determine activity by tissue changes applying the Choi criteria to Soft Tissue Sarcomas (STS)(see radiological review sub study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine toxicity of trabectedin/doxorubicin combination and the control arm.</measure>
    <time_frame>2012</time_frame>
    <description>To determine toxicity of trabectedin/doxorubicin combination and the control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine protein and mRNA expression of genes possibly involved in a potential profile of more favorable response or resistance to study drugs and to analyze the prognostic impact of them on predefined efficacy parameters.</measure>
    <time_frame>2012</time_frame>
    <description>To determine protein and mRNA expression of genes possibly involved in a potential profile of more favorable response or resistance to study drugs and to analyze the prognostic impact of them on predefined efficacy parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate genomic instability, as well as protein expression that could influence response/resistance to the study drugs and make a correlation with efficacy endpoints.</measure>
    <time_frame>2012</time_frame>
    <description>To evaluate genomic instability, as well as protein expression that could influence response/resistance to the study drugs and make a correlation with efficacy endpoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.&#xD;
Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.&#xD;
Route of administration: for intravenous use after reconstitution and further dilution.&#xD;
Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.&#xD;
Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must sign voluntarily the informed consent from before any study test is&#xD;
             conducted that is not part of routine patient care, with the knowledge that he/she can&#xD;
             abandon the study at any time without this affecting his/her previous care.&#xD;
&#xD;
          -  Aged between 18 and 70.&#xD;
&#xD;
          -  Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.&#xD;
&#xD;
          -  The following histological subtypes can be included:&#xD;
&#xD;
               -  Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma)&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Angiosarcoma&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Hemangiopericytoma&#xD;
&#xD;
               -  Neurofibrosarcoma&#xD;
&#xD;
               -  Mixofibrosarcoma&#xD;
&#xD;
               -  Unclassified sarcoma&#xD;
&#xD;
          -  Measurable disease, according to RECIST criteria&#xD;
&#xD;
          -  Performance status 0-2 Eastern Cooperative Oncology Group(ECOG).&#xD;
&#xD;
          -  Adequate bone marrow function (hemoglobin &gt; 10 g/dL, leukocytes ≥ 3.000/mm3,&#xD;
             neutrophils ≥1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤&#xD;
             1,6 mg/dL, transaminases ≤2.5 times the upper limit of normal (ULN), total bilirubin ≤&#xD;
             upper limit of normal (ULN), CPK ≤ 2.5 times upper limit of normal (ULN), alkaline&#xD;
             phosphatase ≤ 2.5 times the upper limit of normal (ULN) are acceptable. If the&#xD;
             increase of alkaline phosphatase is &gt; 2.5 times the upper limit of normal (ULN), then&#xD;
             the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤&#xD;
             upper limit of normal (ULN).&#xD;
&#xD;
          -  Men or women of child bearing potential should be using an effective method of&#xD;
             contraception before entry into the study and throughout the same and for 6 months&#xD;
             after ending the study. Women of childbearing potential must have a negative urine&#xD;
             pregnancy test before study entry.&#xD;
&#xD;
          -  Normal cardiac function with a Left ventricular ejection fraction (LVEF) ≥ 50% by&#xD;
             echocardiogram or Multiple Uptake Gated Acquisition Scan (MUGA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy treatment.&#xD;
&#xD;
          -  Previous radiotherapy involving the only localization(s) of measurable tumoral&#xD;
             disease.&#xD;
&#xD;
          -  Performance status&gt; 2 Eastern Cooperative Oncology Group(ECOG).&#xD;
&#xD;
          -  Central Nervous System (CNS) metastases.&#xD;
&#xD;
          -  Plasma bilirubin &gt; upper limit of normal(ULN).&#xD;
&#xD;
          -  Creatinine &gt; 1.6 mg/dL.&#xD;
&#xD;
          -  History of other neoplastic disease with the exception of basalioma or in situ&#xD;
             cervical cancer adequately treated.&#xD;
&#xD;
          -  Significant cardiovascular disease (for example, dyspnea &gt; 2 NYHA)&#xD;
&#xD;
          -  Significant systemic diseases grade 3 or higher on the NCI-CTC version 3.0 scale, that&#xD;
             limit patient availability, or according to investigator judgment may contribute&#xD;
             significantly to treatment toxicity.&#xD;
&#xD;
          -  Uncontrolled bacterial, mycotic or viral infections.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Psychological, familial, social or geographic circumstances that limit the patient's&#xD;
             ability to comply with the protocol or informed consent.&#xD;
&#xD;
          -  Patients participating in another clinical trial or receiving any other&#xD;
             investigational product.&#xD;
&#xD;
          -  Patients who had participated in another clinical trial and/or had received any other&#xD;
             investigational product in the last 30 days prior to inclusion.&#xD;
&#xD;
          -  The following histologic subtypes are excluded:&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Ewing's family of tumors&#xD;
&#xD;
               -  Desmoplastic small round cell tumor&#xD;
&#xD;
               -  Clear cell sarcoma&#xD;
&#xD;
               -  Alveolar sarcoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martin Broto, PhM</last_name>
    <role>Principal Investigator</role>
    <affiliation>GEIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Poveda, Ph.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GEIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ico Hospitalet</name>
      <address>
        <city>L'Hospitalet</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Provincial Castellón</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Xeral Cies</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Puerta Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico. San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Clinico de Malaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de Navarra</name>
      <address>
        <city>Navarra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. C. Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic STS</keyword>
  <keyword>Trabectedin</keyword>
  <keyword>doxorrubicin</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>non operable sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

